# PUBLIC SUMMARY DOCUMENT

**Product:** Dansac NovaLife 2 Flat GX+ Wafer

**Applicant:** Dansac

**Date of SPAP Meeting:** 20 October 2020

## Proposed Deletion on the Stoma Appliance Scheme

The applicant, Dansac, sought the deletion of two variants from the current listing of Dansac NovaLife 2 Flat GX+ Wafer (SAS Code 80049D) in subgroup 4(b) of the Stoma Appliance Scheme (SAS) Schedule, due to low volume sales and newer technology being available. The product, including nine variants, is currently listed at a unit price of $4.742 with a maximum monthly quantity of 20 units.

## Substitute products

The applicant nominated substitute products, from its own range.

**Variants to be deleted**

| **Product Code** | **Description** |
| --- | --- |
| 1843-30 | no belt loops, mechanical coupling, 43mm ring, floating flange, 1.1mm, hydrocolloid baseplate, hydrocolloid self-adhesive, extended wear, oval, pre-cut, 30mm, release tabs, |
| 1870-50 | no belt loops, mechanical coupling, 70mm ring, floating flange, 1.1mm, hydrocolloid baseplate, hydrocolloid self-adhesive, extended wear, oval, pre-cut, 50mm, release tabs, |

## Background

This product was first listed on the SAS Schedule in April 2016.

## Clinical Place for the Product

The proposed substitute product provides an alternative for users requiring a two-piece baseplate with mechanical coupling.

### Financial Analysis

The deletion of two variants is recommended. The substitute products are currently listed in subgroup 4(b) of the SAS Schedule at the same cost and maximum monthly quantity. It is therefore, unlikely that there would be any budgetary impact for the SAS as a consequence of deleting this product.

## Panel Recommendation

The Panel recommended the deletion of two variants from the product range for Dansac NovaLife 2 Flat GX+ Wafer (SAS Code 80049D) in subgroup 4(b) of the SAS Schedule at the unit price of $4.742 with a maximum monthly quantity of 20 units.

The Panel also noted that Dansac is to advise Stoma Associations, ostomates, Stomal Therapy Nurses and ACSA of the deletion. A period of approximately six months from the date of the Panel’s recommendation (20 October 2020) should be given to allow users of the product to seek a suitable alternative and to enable Stoma Associations to manage their stock levels.

## Context for Decision

The Panel helps decide whether stoma products should be subsidised and, if so, the conditions of their subsidisation in Australia. It considers submissions in this context.
A Panel decision not to recommend listing or changes to a listing does not represent a final Panel view about the merits of a particular stoma product. A company can resubmit to the Panel following a decision not to recommend listing or changes to a listing. The Panel is an advisory committee and as such its recommendations are non-binding on Government.
All Panel recommendations are subject to Cabinet/Ministerial approval.

## Applicant’s Comment

Dansac agrees with SPAP’s recommendation.